Given that olaparib has been approved for metastatic HER2- breast cancer with a germline BRCA mutation [42], it is reasonable to speculate that adding PARPi to treatments of HER2+ breast cancer might be beneficial in the presence of somatic BRCA or HRR mutations. The gene discussed is ERBB2; the disease is breast carcinoma.